This observational study will evaluate the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with active moderate to severe rheumatoid arthritis and an inadequate response to non-biologic disease-modifying anti-rheumatic drugs (DMARDs). Data will be collected from each eligible patient initiating RoActemra/Actemra treatment over 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01617005?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
